Logo
Banner

Monoclonal Antibodies Development Against Superbugs

The emergence of an increasing number of antibiotic-resistant bacteria has revealed an urgent need for new anti-infective drugs to complement the antibiotic arsenal. Monoclonal antibodies can treat bacterial infections by a variety of mechanisms and are often safe and well-tolerated. Antibodies complement antibiotic therapy and have efficacy against resistant strains of bacteria. Ace Infectious offers services for the development of exciting next generation antibodies against superbugs, which include antibodies with different mechanisms of action and different forms of antibodies designed, thus providing new therapeutic mechanisms for a variety of drug-resistant bacteria.

Promising Anti-Superbug Method - Monoclonal Antibody

Antibody therapies have been successfully applied in many therapeutic areas. Given that antibodies can target bacteria, antibodies can also be used as antibiotics to treat specific types of bacterial infections. And the use of monoclonal antibodies can also prevent many acquired drug-resistant bacterial infections, such as Bacillus immobilis, Pseudomonas aeruginosa, Klebsiella pneumoniae, etc. With advances in antibody engineering technology, coupled with low-cost manufacturing methods, this may become a significant growth area for successful treatment of superbugs in the future.

Modes of actions of anti-superbug mAbs.Fig. 1 Modes of actions of anti-superbug mAbs. (Wang H, et al., 2022)

Antitoxin monoclonal antibody therapies inhibit the virulence of drug-resistant bacteria to limit their invasion and damage to the host, while not creating selective pressure on the bacteria to develop new drug resistance. Ace Infectious provides services for the development of antitoxin monoclonal antibody-based superbug therapies, and attempts to design and generate monoclonal antibodies against toxins from drug-resistant bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Clostridium spp. and Escherichia coli.

Various Monoclonal Antibodies Development Services Against Superbugs

  • Antibody therapies against infections have focused on toxin neutralization, and several currently licensed therapies against bacteria target bacterial exotoxins. Antitoxin monoclonal antibody therapies inhibit the virulence of drug-resistant bacteria to limit their invasion and damage to the host, while not creating selective pressure on the bacteria to develop new drug resistance. We provide services for the development of antitoxin monoclonal antibody-based superbug therapies.
  • Depriving pathogens of virulence factors can modulate the pathogenesis of bacteria. Therefore, virulence factor-specific monoclonal antibodies blocking bacterial infection can be applied to the study of superbugs. We offer services for the development of monoclonal antibodies targeting virulence factors, which is a promising alternative approach to fighting superbug infections.
  • Biofilm-associated bacteria often have low susceptibility to antibiotics. Therefore, there is an urgent need to develop innovative therapeutic interventions to prevent biofilm formation or to treat biofilm's that have formed. The use of monoclonal antibodies against biofilms is an attractive measure. We offer services for the development of monoclonal antibodies targeting bacterial biofilms.
  • Monoclonal antibodies have relatively superior efficacy and tolerability in the treatment of drug-resistant bacteria. Despite this, some drug candidates have failed to pass clinical trials. The preparation and characterization process of antibodies is critical in order to obtain the desired efficacy and promising preclinical results. We provide a professional platform for the production and characterization of designed antibodies.

Development Methods

Humanized monoclonal antibodies are currently the dominant form in the field of therapeutic antibodies. We focus on antibody development through three technology platforms related to human antibody generation.

  • Phage display
  • Transgenic mice
  • Single B cell antibody isolation

Antimicrobial monoclonal antibodies against antibiotic-resistant pathogens have great potential as more is learned about the target antigens and their pathogenic effects. We will perform studies of numerous antimicrobial monoclonal antibodies based on different strains of bacteria. Common superbugs include,

  • Staphylococcus aureus
  • Pseudomonas aeruginosa
  • Klebsiella pneumoniae
  • Acinetobacter baumannii
  • Others

To learn more about antibody therapy for superbugs, please contact us.

Reference

  1. Wang H, et al. Anti-bacterial monoclonal antibodies: next generation therapy against superbugs. Appl Microbiol Biotechnol, 2022, 106, 3957–3972.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.